Many more women could be helped by a new type of breast cancer drug, say experts.
有关专家日前表示，随着一种治疗乳腺癌的新药诞生，更多的女性将会得到帮助。
Biological therapies are currently only available as part of clinical trials, but hold great promise. Experts estimate as many as one in five patients might benefit.
虽然生物疗法目前仅对部分临床试验有效，但专家对此仍然持有很大的希望。专家预计，多达五分之一的病患能从中获益。
Around 10,000 women a year in the UK might benefit from a new type of breast cancer treatment, say scientists.
科学家表示，每年会有约10000名英国女性患者将从一种新的乳腺癌治疗手段中获益。
Biological therapies can help fight breast cancers caused by rare, inherited genetic errors like the BRCA one actress Angelina Jolie carries.
生物治疗可以帮助抵抗罕见的遗传错误导致的乳腺癌，例如女演员安吉丽娜·朱莉所携带的乳腺癌易感基因。
Now a new study by experts at the Wellcome Trust Sanger Institute suggests these targeted drugs may also work in many other women who do not have these risky genes.
现在，由威康信托基金会桑格研究所的专家提出的一项新研究表明，这些靶向药物也可能在许多其他没有这些危险基因的女性中发挥作用。

The drugs could be effective in one in five breast cancers, say the researchers. That's 20% of patients - far more than the 1 to 5% who develop the cancer alongside having faulty BRCA genes.
研究人员表示，这些药物可以在五分之一的乳腺癌中有效。这是病患数量的20%--远远超过1%到5%由于携带乳腺癌易感基因而发展成为乳腺癌的患者人数。
One biological therapy or PARP inhibitor, called olaparib, is already used on the NHS to treat advanced ovarian cancer. It is not yet approved as a breast cancer drug, although some UK women are taking it in clinical trials.
一种生物疗法，或者叫做olaparib的PARP抑制剂，已经被英国国民健康保险制度用于治疗晚期卵巢癌。尽管一些英国妇女正在接受临床试验，但它尚未被批准为乳腺癌药物。
For the latest work, published in the journal Nature Medicine, the researchers looked at the genetic make-up of breast cancer in 560 different patients.
对于发表在《自然医学》杂志上的最新研究，研究人员观察了560例不同患者的乳腺癌的基因构成。
They found a significant proportion of them had genetic errors or "mutational signatures" that were very similar to faulty BRCA.
他们发现相当一部分患者有着和乳腺癌易感基因相似的遗传错误或者基因突变。
Given the close similarity, these cancers might be treatable with biological therapies too, they reasoned. They recommended clinical trials to confirm this.
他们认为，由于有着这样的相似性，这些癌症同样可以采用生物疗法。他们建议用临床试验来证明这一点。